News - Mosanna Therapeutics

Apr

Mosanna Therapeutics Announces a Seed Extension Financing Round to Complete Preparations to Enter the Clinic with MOS-118 in Metabolic Obstructive Sleep Apnea

April 11, 2023Jonathan TalbotNews

Company pursuing a highly differentiated small molecule MOS-118 in Metabolic Obstructive Sleep Apnea. New investors, Supermoon Capital and HTGF, join founding investor Forty51 Ventures to complete the Seed syndicate. Company will use the funds to file an IND in preparation for a proof of mechanism and proof of concept in the clinic. Basel, Switzerland, April 11, 2023 /PRNewswire/ – Mosanna Therapeutics AG, a Swiss Biotech company today announced that Supermoon Capital, a US based venture capital...

Dec

Mosanna to participate in the Biotech Showcase™ 2023, 9-11 Jan in San Francisco

December 19, 2022Jonathan TalbotNews

BASEL, December 19, 2022 – Mosanna Therapeutics, a preclinical-stage Biotech company focused on developing MOS-118, a pharmacologic therapy to treat obstructive sleep apnea (OSA), today announced that the CEO will participate in the Partnering Forum at the Biotech Showcase 2023 taking place in San Francisco, January 9-11, and virtually between January 17-18. Meeting schedules will be accessible to registered attendees. To schedule a meeting, please do so via the partneringONE platform.

Oct

Mosanna to Participate in BIO-EUROPE 2022 Partnering Forum

October 19, 2022Jonathan TalbotNews

BASEL, October 19, 2022 – Mosanna Therapeutics, a preclinical-stage Biotech company focused on developing MOS-118, a pharmacologic therapy to treat obstructive sleep apnea (OSA), today announced that the CEO will participate in the Partnering Forum at the BIO-EUROPE 2022 Conference taking place in Liepzig, Germany, October 24-26, and virtually between Nov 2-4, 2022. Meeting schedules will be accessible to registered conference attendees. To schedule a meeting, please do so via the partneringONE platform.

Sep

MedPharm collaborates with Mosanna to develop new drug to tackle Metabolic Obstructive Sleep Apnea

September 21, 2022Jonathan TalbotNews

Read the full announcement here

Jul

Mosanna Therapeutics Announces a Seed Financing Round to Advance Development of MOS-118 to Treat Metabolic Obstructive Sleep Apnea

July 13, 2022Jonathan TalbotNews

Company pursuing an advanced small molecule MOS-118 (formerly known as AVE0118) discovered by Sanofi. Experienced team with strong background in Metabolic Diseases and Obstructive Sleep Apnea. Seed financing led by Forty51 Ventures. Basel, Switzerland, July 13, 2022 /PRNewswire/ — Mosanna Therapeutics AG, a Swiss Biotech company today announced that it has secured seed financing led by Forty51 Ventures to pursue the development of AVE0118 which will be referred to as MOS-118 going forward, a small...